C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Tuesday, up 4.05% from the previous trading day ,before settling in for the closing price of $7.66. Over the past 52 weeks, CCCC has traded in a range of $1.06-$11.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 7.65% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 30.76%. With a float of $57.73 million, this company’s outstanding shares have now reached $60.47 million.
In an organization with 145 employees, it is important to assess its efficiency.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 15.85%, while institutional ownership is 63.54%.
C4 Therapeutics Inc (CCCC) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.7 earnings per share (EPS), lower than consensus estimate (set at -$0.68) by -$0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 6.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.23 million. That was inferior than the volume of 4.0 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 33.47%. Additionally, its Average True Range was 0.59.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 63.86%, which indicates a significant increase from 34.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.03% in the past 14 days, which was lower than the 201.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.26, while its 200-day Moving Average is $4.40. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $8.10. Second resistance stands at $8.24. The third major resistance level sits at $8.48. If the price goes on to break the first support level at $7.72, it is likely to go to the next support level at $7.48. The third support level lies at $7.34 if the price breaches the second support level.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
The company with the Market Capitalisation of 546.74 million has total of 68,601K Shares Outstanding. Its annual sales at the moment are 20,760 K in contrast with the sum of -132,490 K annual income. Company’s last quarter sales were recorded 3,260 K and last quarter income was -34,750 K.
